Humira is a prescription drug used to treat hidradenitis suppurativa (HS). Learn how the drug works, who it’s used for, and more.

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

CVS sees 23% revenue growth in healthcare benefits & projects 10% EPS in 2025, with Aetna recovery boosting performance. Click here to read why CVS is a Hold.

Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ensuring plan sustainability.

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation.

For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, ...

Suppose further research confirms that the transparent model consistently produces savings without sacrificing safety and efficacy.

EAGAN, Minn., Oct. 7, 2024 /PRNewswire/ -- Prime Therapeutics LLC (Prime) today announced new, cost-effective Humira biosimilar solutions, offering clients continued flexibility and choice, along with ...

Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.’s (NYSE:ABBV) Humira, one of the ...

Blue Shield of California partners with Fresenius Kabi and Evio Pharmacy to cut the cost of Humira's biosimilar to $525 per month, with most members paying $0 out of pocket starting January 2025.

Patient advocacy groups are often funded through pharmaceutical companies, but there are currently no regulations governing disclosure of this potential conflict of interest.